Evidence map›Paper›PMID 40385530›Full record

ArticleBioengineering & translational medicine2025

Green/red fluorescent protein disrupting drugs for real-time permeability tracking in three-dimensional tumor spheroids.

Maytal Avrashami, Danna Niezni, Dana Meron Azagury, Hagit Sason, Yosi Shamay

Abstract read
In one paragraph

Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maytal AvrashamiFaculty of Biomedical Engineering Technion - Israel Institute of Technology Haifa Israel.ORCID https://orcid.org/0000-0002-7505-7015
Danna NiezniFaculty of Biomedical Engineering Technion - Israel Institute of Technology Haifa Israel.
Dana Meron AzaguryFaculty of Biomedical Engineering Technion - Israel Institute of Technology Haifa Israel.
Hagit SasonFaculty of Biomedical Engineering Technion - Israel Institute of Technology Haifa Israel.
Yosi ShamayFaculty of Biomedical Engineering Technion - Israel Institute of Technology Haifa Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional (3D) spheroid models offer a more physiologically relevant and complex environment compared to traditional two-dimensional cultures, making them a promising tool for studying tumor biology and drug response. However, these models often face challenges in real-time monitoring of drug diffusion, penetration, and target engagement, limiting their predictive power for in vivo and clinical outcomes. This study introduces a novel approach for real-time tracking of drug permeability using small molecule drugs with GFP/RFP-disrupting properties that correlate with their efficacy. We developed a reproducible 3D spheroid model with various cancer cell lines expressing GFP/RFP for efficient drug screening. Through screening over 20 FDA-approved enzyme inhibitors, we identified three covalent kinase inhibitors-osimertinib, afatinib, and neratinib-that irreversibly disrupt GFP and RFP fluorescence. Our results reveal distinct drug diffusion and penetration profiles within GFP/RFP-expressing spheroids, varying with drug concentration and formulation, and correlating with clinical volume of distribution (Vd) values. Additionally, we demonstrate that our approach is useful for evaluating different drug formulations as well as screening penetration enhancers for solid tumors. These findings offer a valuable 3D model for studying kinetics of drug permeability and efficacy in tumor-like environments, with potential implications for drug delivery research and formulation development.

Indexed as

covalent inhibitorsdrug penetrationfluorescent proteinstumor spheroids

Identifiers

PMID40385530
PMCPMC12079514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.